A large biotech company selected PRA to conduct 2 global Phase III open-label studies to measure the safety and efficacy of a multiple myeloma drug. The studies presented a number of critical challenges to the PRA project team. Through teamwork and strategic planning, PRA developed plans that helped us reach the client’s milestones and resulted in successful site activations and first patient in.
Lupus Awareness Month: Coping with an Autoimmune Disease During a Global Pandemic
Lupus is a chronic autoimmune disease that occurs when your body's immune system attacks your tissues and organs. Inflammation caused by lupus can…
Program Challenges Strengthen Partnership
PRA Health Sciences was selected to conduct a global program of studies that targeted 2,200+ patients with multiple sclerosis (MS). Although there…
Clinical Trials in Children with Impaired Mental Capacity
Download this resource to learn how to conduct studies with patients who lack legal competence and the 4 ethical pillars of medical research.